A new kind of flexible

Article

Breaking news from the floor of ESCRS

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Related Content
A group of elderly women navigate a street in Europe. Concept image for age-related macular degeneration and geographic atrophy. Image credit: ©Zelma – stock.adobe.com

How patients navigate quality-of-life challenges associated with geographic atrophy

Lynda Charters
May 15th 2025
Article

Investigators sought to understand the diagnostic path, symptoms, quality of life impact and coping mechanisms of patients with GA in western Europe and the United States

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A woman holds an ice cube near her face. Concept image for chronic ocular surface pain treatment, EyeCool Therapeutics corneal cooling technology for dry eye disease. Image credit: ©dream@do – stock.adobe.com

EyeCool Therapeutics announces results from pilot study of novel chronic ocular surface pain treatment

Hattie Hayes
May 12th 2025
Article

The investigational device, ETX-4143, was the focus of a study involving 31 patients with COSP in Australia

A series of kidney scans. Concept image for retinal biomarker scan, kidney function, lupus and autoimmune disease. Image credit: ©Sved Oliver – stock.adobe.com

Retinal microvascular changes in patients with systemic lupus erythematosus: Importance of OCTA

Lynda Charters
May 12th 2025
Article

The biomarkers are especially crucial for patients with lupus nephritis

Topcon Healthcare, Inc. appoints Krysten Williams Head of Digital Solutions & Clinical Development – EMEA

Topcon Healthcare, Inc. appoints Krysten Williams Head of Digital Solutions & Clinical Development – EMEA

Sydney M Crago
May 9th 2025
Article

Williams joins Topcon Healthcare from Heidelberg Engineering, where she held multiple senior leadership roles.

Teprotumumab (Tepezza, Amgen) receives marketing authorisation from MHRA

Teprotumumab (Tepezza, Amgen) receives marketing authorisation from MHRA

Kassi Filkins
May 8th 2025
Article

Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK

© 2025 MJH Life Sciences

All rights reserved.